These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29572677)

  • 1. A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients.
    Cai H; Guo W; Zhang S; Li N; Wang X; Liu H; Chen R; Wang S; Guo Z; Li J
    Breast Cancer Res Treat; 2018 Jul; 170(2):271-277. PubMed ID: 29572677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A qualitative transcriptional signature to reclassify histological grade of ER-positive breast cancer patients.
    Li J; Jiang W; Liang Q; Liu G; Dai Y; Zheng H; Yang J; Cai H; Zheng G
    BMC Genomics; 2020 Apr; 21(1):283. PubMed ID: 32252627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer.
    Cai H; Li X; Li J; Ao L; Yan H; Tong M; Guan Q; Li M; Guo Z
    Oncotarget; 2015 Dec; 6(42):44593-608. PubMed ID: 26527319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
    Miller PC; Clarke J; Koru-Sengul T; Brinkman J; El-Ashry D
    Clin Cancer Res; 2015 Jan; 21(2):373-85. PubMed ID: 25370469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor.
    Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK
    Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings.
    Li M; Li H; Hong G; Tang Z; Liu G; Lin X; Lin M; Qi L; Guo Z
    BMC Cancer; 2019 Jan; 19(1):67. PubMed ID: 30642283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy.
    Li X; Huang H; Zhang J; Jiang F; Guo Y; Shi Y; Guo Z; Ao L
    Prostate; 2020 Apr; 80(5):376-387. PubMed ID: 31961962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples.
    Chen R; Guan Q; Cheng J; He J; Liu H; Cai H; Hong G; Zhang J; Li N; Ao L; Guo Z
    Oncotarget; 2017 Jan; 8(4):6652-6662. PubMed ID: 28036264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of key genes relevant to the prognosis of ER-positive and ER-negative breast cancer based on a prognostic prediction system.
    Xiao B; Hang J; Lei T; He Y; Kuang Z; Wang L; Chen L; He J; Zhang W; Liao Y; Sun Z; Li L
    Mol Biol Rep; 2019 Apr; 46(2):2111-2119. PubMed ID: 30888555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circumvent the uncertainty in the applications of transcriptional signatures to tumor tissues sampled from different tumor sites.
    Cheng J; Guo Y; Gao Q; Li H; Yan H; Li M; Cai H; Zheng W; Li X; Jiang W; Guo Z
    Oncotarget; 2017 May; 8(18):30265-30275. PubMed ID: 28427173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status.
    Li Q; Eklund AC; Juul N; Haibe-Kains B; Workman CT; Richardson AL; Szallasi Z; Swanton C
    PLoS One; 2010 Dec; 5(12):e15031. PubMed ID: 21152022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prognostic eight-lncRNA expression signature in predicting recurrence of ER-positive breast cancer receiving endocrine therapy.
    Tang J; Cui Q; Zhang D; Kong D; Liao X; Ren J; Gong Y; Wu G
    J Cell Physiol; 2020 May; 235(5):4746-4755. PubMed ID: 31663114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A triple hormone receptor ER, AR, and VDR signature is a robust prognosis predictor in breast cancer.
    Omar M; Harrell JC; Tamimi R; Marchionni L; Erdogan C; Nakshatri H; Ince TA
    Breast Cancer Res; 2024 Sep; 26(1):132. PubMed ID: 39272208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.
    Lehmann BD; Ding Y; Viox DJ; Jiang M; Zheng Y; Liao W; Chen X; Xiang W; Yi Y
    BMC Cancer; 2015 Mar; 15():179. PubMed ID: 25886164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
    Risi E; Grilli A; Migliaccio I; Biagioni C; McCartney A; Guarducci C; Bonechi M; Benelli M; Vitale S; Biganzoli L; Bicciato S; Di Leo A; Malorni L
    Breast Cancer Res Treat; 2018 Jul; 170(2):329-341. PubMed ID: 29564743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes linked to expression of gene subsets for protein hormones and their cognate receptors from LCM-procured breast carcinoma cells.
    Daniels MW; Brock GN; Wittliff JL
    Breast Cancer Res Treat; 2017 Jan; 161(2):245-258. PubMed ID: 27858316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer.
    Zhou X; Wang X; Huang Z; Xu L; Zhu W; Liu P
    J Exp Clin Cancer Res; 2014 Nov; 33(1):94. PubMed ID: 25373603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors.
    Luo J; Liu S; Leung S; Gru AA; Tao Y; Hoog J; Ho J; Davies SR; Allred DC; Salavaggione AL; Snider J; Mardis ER; Nielsen TO; Ellis MJ
    J Mol Diagn; 2017 Jan; 19(1):147-161. PubMed ID: 27993329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.